Last reviewed · How we verify
BMS-582949 and Methotrexate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BMS-582949 and Methotrexate (BMS-582949 and Methotrexate) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BMS-582949 and Methotrexate TARGET | BMS-582949 and Methotrexate | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BMS-582949 and Methotrexate CI watch — RSS
- BMS-582949 and Methotrexate CI watch — Atom
- BMS-582949 and Methotrexate CI watch — JSON
- BMS-582949 and Methotrexate alone — RSS
Cite this brief
Drug Landscape (2026). BMS-582949 and Methotrexate — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-582949-and-methotrexate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab